Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 43.42 USD 2.7% Market Closed
Market Cap: 883.2m USD

Net Margin
Nektar Therapeutics

-192.9%
Current
-271%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-192.9%
=
Net Income
-120.7m
/
Revenue
62.6m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Nektar Therapeutics
NASDAQ:NKTR
853.3m USD
-193%
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
31%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
485.6B USD
27%
CH
Roche Holding AG
SIX:ROG
257.9B CHF
15%
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP
16%
US
Merck & Co Inc
NYSE:MRK
265B USD
30%
CH
Novartis AG
SIX:NOVN
207.5B CHF
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
33%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
-126%
US
Pfizer Inc
NYSE:PFE
142.8B USD
16%
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
853.3m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
2.12 USD
Overvaluation 95%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-192.9%
=
Net Income
-120.7m
/
Revenue
62.6m
What is the Net Margin of Nektar Therapeutics?

Based on Nektar Therapeutics's most recent financial statements, the company has Net Margin of -192.9%.

Back to Top